Long‐term outcomes after prophylactic ICD and CRT‐D implantation in nonischemic patients: Analysis from a nationwide database of daily remote‐monitoring transmissions
暂无分享,去创建一个
A. Capucci | A. Curnis | M. Biffi | F. Quartieri | P. Della Bella | C. Pignalberi | V. Calvi | E. Pisano | G. Forleo | F. Solimene | G. Zanotto | A. D'onofrio | G. Maglia | S. Iacopino | M. Manzo | D. Giacopelli | A. Gargaro | G. Senatore | F. Caravati | M. Santamaria | A. D’Onofrio | E. Pisanò | Matteo Santamaria
[1] P. Della Bella,et al. Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: A survey from the Home Monitoring Expert Alliance project , 2018, Clinical cardiology.
[2] G. Hindricks,et al. Remote monitoring and clinical outcomes: details on information flow and workflow in the IN-TIME study , 2018, European heart journal. Quality of care & clinical outcomes.
[3] Lurdes Y. T. Inoue,et al. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age? , 2017, Circulation.
[4] Michael J Ackerman,et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.
[5] William J. Bryant,et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.
[6] Y. Reddy,et al. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2017, JACC. Clinical electrophysiology.
[7] S. Solomon,et al. Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.
[8] Z. Whinnett,et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials , 2017, European heart journal.
[9] L. Fauchier,et al. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[10] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[11] P. Kirchhof,et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.
[12] C. O'connor,et al. Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy: Report From IMPROVE HF , 2010, Circulation. Heart failure.
[13] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[14] Akshay S. Desai,et al. Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .
[15] Hugh Calkins,et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.
[16] A. Kadish,et al. DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.
[17] F. Morady,et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.
[18] K. Kuck,et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.
[19] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[20] Á. Arenal,et al. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis. , 2019, International journal of cardiology.
[21] M. Cheitlin. Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy , 2007 .